(Q46703841)

English

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ruben Niesvizky

5

object named as

Ruben Niesvizky

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

author name string

Morton Coleman

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Peter Martin

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Jia Ruan

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Richard Furman

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Rebecca Elstrom

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Patricia George

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Thomas P Kaufman

8

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

John P Leonard

9

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

language of work or name

0 references

publication date

1 May 2008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

112

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

10

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

2228-2232

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

High dose methotrexate with citrovorum factor in adult resistant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

New drugs for the treatment of advanced-stage diffuse large cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

21 January 2018

COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23422

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23422

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/18338745

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46703841&oldid=2127606209"